The majority of diseases are associated with alterations in multiple molecular pathways and
complex interactions at the cellular and organ levels. Single-target monotherapies therefore …

Drugs designed to act against individual molecular targets cannot usually combat multigenic
diseases such as cancer, or diseases that affect multiple tissues or cell types such as …

Understanding the molecular mechanisms underlying synergistic, potentiative and
antagonistic effects of drug combinations could facilitate the discovery of novel efficacious …

Cancer therapies that target key molecules have not fulfilled expected promises for most
common malignancies. Major challenges include the incomplete understanding and …

Highlights•Optimal drug combinations require understanding of the drug-induced changes
in cellular states.•The dynamics of signaling molecules can be reporters for cellular states …

Gene products or pathways that are aberrantly activated in cancer but not in normal tissue
hold great promises for being effective and safe anticancer therapeutic targets. Many …

The biological redundancies in molecular networks of complex diseases limit the efficacy of
many single drug therapies. Combination therapeutics, as a common therapeutic method …

Drug combinations are an increasingly favored strategy for increasing therapeutic windows
for potential drugs, but enthusiasm for this approach is tempered by concerns that …

Combination chemotherapies have been a mainstay in the treatment of disseminated
malignancies for almost 60 y, yet even successful regimens fail to cure many patients …

Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …